INDOCO Indoco Remedies Q3 FY26 results (Oct–Dec 2025) and concall
Indoco Remedies delivered a strong Q3 FY26 with consolidated revenue growth of 7.9% YoY and significant EBITDA margin expansion, primarily driven by robust performance in International Formulations and API segments. The domestic business remained flat due to acute therapy challenges, while one-time costs for remediation and penalties impacted profitability. Management expressed confidence in future growth, particularly in Europe and API, with strategic initiatives in OTC and subchronic portfolios.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 8.3%, net profit down 3.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 411 | 390 | 440 | 485 | 445 +8% |
| EBITDA | 12 | -1 | 18 | 43 | 32 +167% |
| Net profit | -28 | -41 | -36 | -9 | -29 −4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
